Literature DB >> 36040642

USP17L2-SIRT7 axis regulates DNA damage repair and chemoresistance in breast cancer cells.

Yang Su1,2, Chenming Wu1, Yiming Chang3, Lei Li1, Yuping Chen1, Xuebing Jia4, Xinshu Wang3, Ying Lv1, Bentong Yu5,6, Jian Yuan7,8,9.   

Abstract

PURPOSE: Sirtuin7 (SIRT7), as a member of the sirtuin and NAD+-dependent protein-modifying enzyme family, plays an important role in regulating cellular metabolism, stress responses, tumorigenesis, and aging. Ubiquitination and deubiquitination are reversible post-translational modifications that regulate protein stability, enzyme activity, protein-protein interactions, and cellular signaling transduction. However, whether SIRT7 is regulated by deubiquitination signaling is unclear. This study aims to elucidate the molecular mechanism of SIRT7 via deubiquitination signaling.
METHODS: USP17L2 or SIRT7-targeting shRNAs were used to deplete USP17L2 or SIRT7. Western blot was applied to assess the effects of USP17L2 or SIRT7 depletion. A co-immunoprecipitation assay was used to detect the interaction relationship. Cell Counting Kit-8 assays were applied to assess the viability of breast cancer cells. An immunohistochemistry assay was employed to detect the protein level in samples from breast cancer patients, and the TCGA database was applied to analyze the survival rate of breast cancer patients. Statistical analyses were performed with the Student's t test (two-tailed unpaired) and χ2 test.
RESULTS: We find that the deubiquitinase USP17L2 interacts with and deubiquitinates SIRT7, thereby increasing SIRT7 protein stability. In addition, USP17L2 regulates DNA damage repair through SIRT7. Furthermore, SIRT7 polyubiquitination is increased by knocking down of USP17L2, which leads to cancer cells sensitizing to chemotherapy. In breast cancer patient samples, high expression of USP17L2 is correlated with increased levels of SIRT7 protein. In conclusion, our study demonstrates that the USP17L2-SIRT7 axis is the new regulator in DNA damage response and chemo-response, suggesting that USP17L2 may be a prognostic factor and a potential therapeutic target in breast cancer.
CONCLUSION: Our results highlighted that USP17L2 regulates the chemoresistance of breast cancer cells in a SIRT7-dependent manner. Moreover, the role of USP17L2 as a potential therapeutic target in breast cancer and a prognostic factor for patients was elucidated.
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Chemoresistance; DNA damage repair; Deubiquitination; SIRT7; USP17L2

Mesh:

Substances:

Year:  2022        PMID: 36040642     DOI: 10.1007/s10549-022-06711-3

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.624


  46 in total

1.  Stem cell aging. A mitochondrial UPR-mediated metabolic checkpoint regulates hematopoietic stem cell aging.

Authors:  Mary Mohrin; Jiyung Shin; Yufei Liu; Katharine Brown; Hanzhi Luo; Yannan Xi; Cole M Haynes; Danica Chen
Journal:  Science       Date:  2015-03-20       Impact factor: 47.728

2.  Sirtuin 7-mediated deacetylation of WD repeat domain 77 (WDR77) suppresses cancer cell growth by reducing WDR77/PRMT5 transmethylase complex activity.

Authors:  Hao Qi; Xiaoyan Shi; Miao Yu; Boya Liu; Minghui Liu; Shi Song; Shuaiyi Chen; Junhua Zou; Wei-Guo Zhu; Jianyuan Luo
Journal:  J Biol Chem       Date:  2018-10-03       Impact factor: 5.157

3.  Sirtuin7 oncogenic potential in human hepatocellular carcinoma and its regulation by the tumor suppressors MiR-125a-5p and MiR-125b.

Authors:  Jeong Kyu Kim; Ji Heon Noh; Kwang Hwa Jung; Jung Woo Eun; Hyun Jin Bae; Min Gyu Kim; Young Gyoon Chang; Qingyu Shen; Won Sang Park; Jung Young Lee; Jürgen Borlak; Suk Woo Nam
Journal:  Hepatology       Date:  2013-02-11       Impact factor: 17.425

4.  Novel protein-protein interactions of TPPII, p53, and SIRT7.

Authors:  Jarmila Nahálková
Journal:  Mol Cell Biochem       Date:  2015-07-14       Impact factor: 3.396

5.  SIRT7 links H3K18 deacetylation to maintenance of oncogenic transformation.

Authors:  Matthew F Barber; Eriko Michishita-Kioi; Yuanxin Xi; Luisa Tasselli; Mitomu Kioi; Zarmik Moqtaderi; Ruth I Tennen; Silvana Paredes; Nicolas L Young; Kaifu Chen; Kevin Struhl; Benjamin A Garcia; Or Gozani; Wei Li; Katrin F Chua
Journal:  Nature       Date:  2012-07-05       Impact factor: 49.962

6.  Altered sirtuin expression is associated with node-positive breast cancer.

Authors:  N Ashraf; S Zino; A Macintyre; D Kingsmore; A P Payne; W D George; P G Shiels
Journal:  Br J Cancer       Date:  2006-09-26       Impact factor: 7.640

7.  SIRT7 antagonizes TGF-β signaling and inhibits breast cancer metastasis.

Authors:  Xiaolong Tang; Lei Shi; Ni Xie; Zuojun Liu; Minxian Qian; Fanbiao Meng; Qingyang Xu; Mingyan Zhou; Xinyue Cao; Wei-Guo Zhu; Baohua Liu
Journal:  Nat Commun       Date:  2017-08-22       Impact factor: 14.919

8.  SIRT7 activates p53 by enhancing PCAF-mediated MDM2 degradation to arrest the cell cycle.

Authors:  Ya-Fei Lu; Xiao-Peng Xu; Xiao-Peng Lu; Qian Zhu; Ge Liu; Yan-Tao Bao; He Wen; Ying-Lu Li; Wei Gu; Wei-Guo Zhu
Journal:  Oncogene       Date:  2020-05-13       Impact factor: 9.867

9.  SIRT7-mediated ATM deacetylation is essential for its deactivation and DNA damage repair.

Authors:  Ming Tang; Zhiming Li; Chaohua Zhang; Xiaopeng Lu; Bo Tu; Ziyang Cao; Yinglu Li; Yongcan Chen; Lu Jiang; Hui Wang; Lina Wang; Jiadong Wang; Baohua Liu; Xingzhi Xu; Haiying Wang; Wei-Guo Zhu
Journal:  Sci Adv       Date:  2019-03-27       Impact factor: 14.136

10.  A SIRT7-dependent acetylation switch of GABPβ1 controls mitochondrial function.

Authors:  Dongryeol Ryu; Young Suk Jo; Giuseppe Lo Sasso; Sokrates Stein; Hongbo Zhang; Alessia Perino; Jung Uee Lee; Massimo Zeviani; Raymond Romand; Michael O Hottiger; Kristina Schoonjans; Johan Auwerx
Journal:  Cell Metab       Date:  2014-09-04       Impact factor: 27.287

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.